论文部分内容阅读
内皮祖细胞(endothelial progenitor cells,EPCs)自1997年被发现和认识后,改变了人们对血管生成的认知。EPCs在特定的细胞因子诱导下分化为血管内皮细胞,并参与血管新生。随着对EPCs研究的深入,其在心血管疾病发病机制和治疗方面的研究也有了重大突破。阿司匹林具有抗血小板聚集作用,被广泛应用于脑卒中、心肌梗死等心血管疾病的一级、二级预防。近年研究发现,低剂量阿司匹林通过其抗血小板聚集作用可增强EPCs功能,改善血管内皮功能,进而恢复内皮依赖性血管舒张功能。因此,了解阿司匹林对EPCs的影响及其可能的机制具有重要的临床意义。
Endothelial progenitor cells (EPCs) have been discovered and recognized since 1997, and have changed the cognition of angiogenesis. EPCs differentiate into vascular endothelial cells under the induction of specific cytokines and participate in angiogenesis. With the deepening of EPCs research, its research on the pathogenesis and treatment of cardiovascular diseases has also made a major breakthrough. Aspirin has an anti-platelet aggregation effect and is widely used in primary and secondary prevention of cardiovascular diseases such as stroke and myocardial infarction. In recent years, the study found that low-dose aspirin through its anti-platelet aggregation can enhance the function of EPCs, improve endothelial function, thereby restoring endothelium-dependent vasodilation. Therefore, to understand the impact of aspirin on EPCs and its possible mechanism has important clinical significance.